Open AccessLipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough
Author(s) -
Markus G. Mohaupt
Publication year - 2016
Publication title -
schweizerische medizinische wochenschrift
Language(s) - English
Resource type - Journals
ISSN - 0036-7672
DOI - 10.4414/smw.2016.14345
Subject(s) - medicine , pcsk9 , block (permutation group theory) , pharmacology , cholesterol , ldl receptor , lipoprotein , geometry , mathematics
While primary prevention of cardiovascular disease primarily involves addressing several risk factors and should also include shared decision-making between patient and treating physician on the preferred means to achieve this goal, only extremes of the dyslipidaemias are targeted by treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom